Adam Nowicki

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak et al. · The Lancet Oncology · 2023 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Dominik Dytfeld, Magdalena Łuczak, Tomasz Wróbel et al. · Oncotarget · 2016 · 68 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.

Lidia Gil, Jan Styczyński, Dominik Dytfeld et al. · PubMed · 2008 · 27 citations

Medicine, Oncology, Pharmacology +15

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience

Anna Czyż, Anna Łojko‐Dankowska, Dominik Dytfeld et al. · Medical Oncology · 2013 · 22 citations · Full text

Medicine, Hematology, Oncology +17

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Magdalena Łuczak, Tadeusz Kubicki, Zuzanna Rzetelska et al. · Polskie Archiwum Medycyny Wewnętrznej · 2017 · 18 citations

Medicine, Oncology, Pharmacology +17